机译:基于细胞的筛查确定帕罗西汀为糖尿病性内皮功能障碍的抑制剂
Department of Anesthesiology, University of Texas Medical Branch,Galveston, Texas;
Department of Anesthesiology, University of Texas Medical Branch,Galveston, Texas;
Department of Anesthesiology, University of Texas Medical Branch,Galveston, Texas;
Department of Anesthesiology, University of Texas Medical Branch,Galveston, Texas;
Department of Anesthesiology, University of Texas Medical Branch,Galveston, Texas;
Department of Anesthesiology, University of Texas Medical Branch,Galveston, Texas;
Department of Anesthesiology, University of Texas Medical Branch,Galveston, Texas;
机译:通过基于细胞的高通量筛选确定的血管生成抑制剂:特异性抑制内皮细胞增殖的3-[((E)-styryl] benzamides)的合成,构效关系和生物学评估
机译:通过基于细胞的高通量筛选确定的血管生成抑制剂:特异性抑制内皮细胞增殖的3-[((E)-styryl] benzamides)的合成,构效关系和生物学评估
机译:用于小分子MYB抑制剂的基于细胞的筛选测定鉴定鼠毒毒素替氏素苷和依托普齐,作为MYB活性的抑制剂
机译:水杨酸钠对糖尿病小鼠冠状动脉耐药性和内皮功能障碍的影响
机译:靶向糖尿病内皮功能障碍中的内质网胁迫的治疗方法
机译:基于细胞的筛查确定帕罗西汀为糖尿病性内皮功能障碍的抑制剂
机译:基于细胞的筛选将帕罗西汀鉴定为糖尿病内皮功能障碍的抑制剂